Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 29;16(11):e0259527.
doi: 10.1371/journal.pone.0259527. eCollection 2021.

Evaluation of a novel, rapid antigen detection test for the diagnosis of SARS-CoV-2

Affiliations

Evaluation of a novel, rapid antigen detection test for the diagnosis of SARS-CoV-2

Rainer Thell et al. PLoS One. .

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) is currently finally determined in laboratory settings by real-time reverse-transcription polymerase-chain-reaction (rt-PCR). However, simple testing with immediately available results are crucial to gain control over COVID-19. The aim was to evaluate such a point-of-care antigen rapid test (AG-rt) device in its performance compared to laboratory-based rt-PCR testing in COVID-19 suspected, symptomatic patients.

Methods: For this prospective study, two specimens each of 541 symptomatic female (54.7%) and male (45.3%) patients aged between 18 and 95 years tested at five emergency departments (ED, n = 296) and four primary healthcare centres (PHC, n = 245), were compared, using AG-rt (positive/negative/invalid) and rt-PCR (positive/negative and cycle threshold, Ct) to diagnose SARS-CoV-2. Diagnostic accuracy, sensitivity, specificity, positive predictive values (PPV), negative predictive value (NPV), and likelihood ratios (LR+/-) of the AG-rt were assessed.

Results: Differences between ED and PHC were detected regarding gender, age, symptoms, disease prevalence, and diagnostic performance. Overall, 174 (32.2%) were tested positive on AG-rt and 213 (39.4%) on rt-PCR. AG correctly classified 91.7% of all rt-PCR positive cases with a sensitivity of 80.3%, specificity of 99.1%, PPV of 98.3, NPV of 88.6%, LR(+) of 87.8, and LR(-) of 0.20. The highest sensitivities and specificities of AG-rt were detected in PHC (sensitivity: 84.4%, specificity: 100.0%), when using Ct of 30 as cut-off (sensitivity: 92.5%, specificity: 97.8%), and when symptom onset was within the first three days (sensitivity: 82.9%, specificity: 99.6%).

Conclusions: The highest sensitivity was detected with a high viral load. Our findings suggest that AG-rt are comparable to rt-PCR to diagnose SARS-CoV-2 in COVID-19 suspected symptomatic patients presenting both at emergency departments and primary health care centres.

PubMed Disclaimer

Conflict of interest statement

The authors have read the journal’s policy and have the following competing interests: Roche Diagnostics provided support for this study in the form of funds sent to the scientific association Science Center Donaustadt, which were used to cover the costs of the test materials and statistician. There are no patents, products in development or marketed products associated with this research to declare. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Figures

Fig 1
Fig 1. Overall testing outcome.
Fig 2
Fig 2. Sensitivities (in % with 95% confidence interval in parenthesis) between ED and PHC regarding days of symptom onset.
Fig 3
Fig 3. Sensitivities (in % with 95% confidence interval in parenthesis) between ED and PHC regarding rt-PCR cut offs.
Fig 4
Fig 4. Boxplot showing cycle threshold (Ct) values of true positive (n = 165) and false negative (n = 37).

Similar articles

Cited by

References

    1. Wang Y, Kang H, Liu X, Tong Z. Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. J Med Virol 2020; 92(6): 538–9. doi: 10.1002/jmv.25721 - DOI - PMC - PubMed
    1. CDC. Centers for Disease Control and Prevention. ARS-CoV-2 Testing Strategy: Considerations for Non-Healthcare Workplaces. 21 October 2020.
    1. ECDPC. European Centre for Disease Prevention and Control. COVID-19 testing strategies and objectives. 15 September 2020.
    1. Okba NMA, Muller MA, Li W, et al.. Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis 2020; 26(7): 1478–88. doi: 10.3201/eid2607.200841 - DOI - PMC - PubMed
    1. Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. J Clin Microbiol 2020; 58(6). doi: 10.1128/JCM.00512-20 - DOI - PMC - PubMed

Publication types

Substances